RxDoctor Payments Data

James Egel, MD

Nephrology · Ashland, KYNPI 1750375135

Payments from drug & device makers

$2,182in general payments, 2019–2025

Across 117 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • Otsuka America Pharmaceutical, Inc.$496
  • AstraZeneca$115
  • Akebia Therapeutics Inc$81
  • OPKO Pharmaceuticals, LLC$75
  • Vifor Pharma, Inc.$67
  • plus $313 from 8 others

What the payments were for

  • Food & beverage$2,04093%
  • Education$1427%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,182 in reported general payments places this provider in the 60th percentile of 165 nephrology providers in Kentucky.

See all nephrology providers in Kentucky

Medicare billing

Part B allowed, 2024
$85,123
Medicare patients
289
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone73$73,884
JardianceEmpagliflozin13$19,226
Sevelamer Carbonate39$2,594
Torsemide58$738
Hydralazine Hcl45$676
Losartan Potassium72$670
Furosemide81$602
Nifedipine ErNifedipine32$551
Calcitriol38$548
Metolazone29$442
Spironolactone64$431
Potassium Chloride34$379
Rosuvastatin Calcium14$360
Bumetanide15$319
Lisinopril50$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$1,036$73,88473 claims
Boehringer IngelheimJardiance$34$19,22613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 165 nephrology providers in Kentucky.

Other nephrology in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →